Pfizer Inc. today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab ...

Empirical vitamin D may lower respiratory infection risk in children * In adults 75+, supplementation could reduce all-cause ...

Lepodisiran, a long-duration small interfering RNA targeting lipoprotein(a) synthesis, reduced serum concentrations of lipoprotein(a) compared to placebo in adults with elevated levels. 2. Lepodisiran ...